Nalfurafine
From Wikipedia, the free encyclopedia
|
Nalfurafine
|
|
| Systematic (IUPAC) name | |
| (E)-N-[17-(cyclopropylmethyl)-4,5α-epoxy- 3,14-dihydroxymorphinan-6β-yl]-3-(furan-3-yl)- N-methylprop-2-enamide |
|
| Identifiers | |
| CAS number | |
| ATC code | ? |
| PubChem | |
| Chemical data | |
| Formula | C28H32N2O5 |
| Mol. mass | 476.564 g/mol |
| Synonyms | TRK-820 |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | intravenous |
Nalfurafine (INN and USAN; also known as AC-820, TRK-820) is a κ-opioid receptor agonist being developed as a treatment for uremic pruritus in people undergoing hemodialysis.
[edit] External links
- http://www.ama-assn.org/ama1/pub/upload/mm/365/nalfurafine_hcl.pdf
- http://www.acologix.com/pipeline_ac-820.html

